ID 110869
著者
ニシムラ, ナオキ Division of Pulmonary Medicine, St. Luke’s International Hospital
スギウラ, リカ Division of Pulmonary Medicine, St. Luke’s International Hospital
ウエダ, ヒロタカ Division of Pulmonary Medicine, St. Luke’s International Hospital
オオノ, ヒロシ Division of Pulmonary Medicine, St. Luke’s International Hospital
ホリノウチ, ヒデヒト Division of Pulmonary Medicine, St. Luke’s International Hospital
ウチヤマ, ノボル Division of Pulmonary Medicine, St. Luke’s International Hospital
チョウナバヤシ, ナオヒコ Division of Pulmonary Medicine, St. Luke’s International Hospital
キーワード
non-small cell lung cancer
gemcitabine
UFT
uracil-tegafur
second-line chemotherapy
資料タイプ
学術雑誌論文
抄録
Gemcitabine plus UFT combination chemotherapy are highly effective and less toxic in the first line setting in patients with non-small cell lung cancer (NSCLC). The purpose of the study is to confirm the feasibility of this regimen as secondor third-line therapy in NSCLC. Methods : Fifteen patients with performance status of 0-1 were enrolled. UFT (tegafur 250 mg/m2/day) was administered orally twice a day from days 1-14, and gemcitabine of 900 mg/m2 was administered intravenously on days 8 and 15 every three weeks on an outpatient setting. The treatment was repeated for at least 3 cycles and continued unless the disease progressed. Results : The response rate and the disease control rate were 6.7% and 66.7%, respectively. Grade 3-4 toxicities included neutropenia in one patient and elevation of transaminases in one patient. The mean relative dose intensity of gemcitabine and UFT were 0.93 and 0.97, respectively. Conclusion : High disease control rate and less toxicity suggested the potential of gemcitabine and UFT combination chemotherapy as second- or third-line therapy in NSCLC.
掲載誌名
The journal of medical investigation : JMI
ISSN
13431420
cat書誌ID
AA11166929
55
3-4
開始ページ
260
終了ページ
266
並び順
260
発行日
2008-08
フルテキストファイル
言語
eng
著者版フラグ
出版社版